Die extrakorporale Photopherese (ECP) ist ein seit fast 4 Jahrzehnten etabliertes
immunmodulatorisches Aphereseverfahren. Ursprünglich zur Therapie des kutanen
T-Zell-Lymphoms entwickelt, hat sie sich als adjuvante oder alternative
Behandlung bei Transplantatabstoßungen solider Organe bewährt. Aktuelle Studien
zeigen insbesondere bei Herz- und Lungentransplantierten eine signifikante
Reduktion akuter und chronischer Rejektionsereignisse bei guter
Verträglichkeit.
Abstract
Extracorporeal Photopheresis (ECP) represents an immunomodulatory treatment.
During ECP, mononuclear cells are separated from peripheral blood and incubated
with 8-MOP. Thereafter these cells are irradiated with UVA and reinfused into
the patient. ECP treatment has been clinically established for more than 30
years and is generally very well tolerated. ECP has been used long-term for the
treatment of cutaneous T-cell lymphomas, acute and chronic GvHD. Beyond that, it
is a therapeutic modality for prophylaxis and treatment of solid organ
rejection, too. There is good evidence regarding the efficacy of ECP in
prevention and treatment of rejection after heart transplantation. The
usefulness of ECP in the treatment of chronic rejection after lung
transplantation has been reported in retrospective trials and recently also in
prospective randomized studies. To date, there are only case reports regarding
therapeutic efficacy of ECP in the rejection after kidney transplantation. ECP
could be a valuable complementary component of therapeutic protocols for
prophylaxis and treatment of acute rejection following liver transplantation.
Nevertheless, prospective controlled trials are urgently needed to support
systematic application of ECP in these indications.
Schlüsselwörter
extrakorporale Photopherese - Organtransplantation - Immunmodulation
Keywords
extracorporeal photopheresis - organ transplantation - immunomodulation